Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 16.67 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $45.689 million which beat the analyst consensus estimate of $34.016 million by 34.32 percent. This is a 118.37 percent increase over sales of $20.923 million the same period last year.